Brand-Name vs Compounded GLP-1s: Cost and Safety Differences

For two years, the math behind compounded GLP-1s looked simple. A brand-name pen had a list price above $1,000 a month, and a compounded vial of “the same” active ingredient cost around $200. For millions of people paying out of pocket, that gap made the decision for them.

In late 2026, that comparison no longer matches what most self-pay patients actually see. Brand-name prices have dropped sharply through the manufacturers’ own pharmacies, new GLP-1 pills have arrived at lower prices, and FDA has tightened the rules on compounding. This guide compares real monthly costs, explains what the price difference does and does not buy, and walks through the safety and legal differences. It is general education, not medical advice, and it does not recommend any product.

The short answer

Compounded GLP-1s are still often cheaper on sticker price, but the gap has shrunk, and the lower price comes with real trade-offs.

• Typical compounded cost: one price tracker scoring 28 compounded programs found an all-in median of $176 a month, with a range of $79 to $348.
• Brand-name self-pay now starts at $149 a month for the Wegovy pill and the Foundayo pill. Wegovy injections are $199 a month for the first two low-dose fills for new patients (through December 31, 2026), then $349. Zepbound runs $299 to $449.
• With insurance or Medicare coverage, brand usually wins outright, often at $25 to $50 a month.
• Compounded drugs are not FDA-approved. FDA does not review them for safety, effectiveness or quality, and they are not generics.

If you are just starting to research costs, our hub on GLP-1 costs without insurance collects every price guide in one place.

What “brand-name” and “compounded” actually mean

Brand-name GLP-1s are the products made by the drug’s manufacturer and approved by FDA after large clinical trials: Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide), and the GLP-1 pills, including the Wegovy pill and Foundayo (orforglipron). Each approved product has a fixed formula, standard strengths, a factory inspected by FDA, and a label that lists known risks. Our guide to FDA-approved GLP-1s for weight loss lists them all.

Compounded GLP-1s are made by a pharmacy that has no connection to the manufacturer. Compounding has a legitimate role, such as making a liquid version of a pill for a child or leaving out an ingredient someone is allergic to. During the 2022 to 2024 shortages, FDA allowed pharmacies to compound semaglutide and tirzepatide so patients were not left without treatment.

Three facts matter most:

1. Compounded is not generic. FDA stresses that generic drugs are FDA-approved and compounded drugs are not. There is no generic semaglutide or tirzepatide in the US.
2. “Same active ingredient” is not guaranteed. FDA has received reports of compounders using salt forms, such as semaglutide sodium or semaglutide acetate. FDA calls these different active ingredients from the one in approved drugs, and says it knows of no lawful basis for compounding with them.
3. Formulas vary by pharmacy. A pharmacist explaining compounded semaglutide on YouTube put it simply: there is no standard recipe, and each pharmacy decides what goes in, including preservatives and add-ons like vitamin B12 or L-carnitine.

Brand vs compounded prices in 2026: the side-by-side

The table below shows self-pay prices for one month without insurance, as published by the manufacturers in fall 2026. Prices change often, so always check the current page before deciding.

For today’s manufacturer prices by dose, see our GLP-1 Price Tracker, which is checked daily.

Option	Typical self-pay price per month	What’s included	Notes
Wegovy pill (oral semaglutide), NovoCare	$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg)	Medication only	Month is 30 tablets
Wegovy injection, NovoCare	$199 for the first 2 low-dose fills for new patients (through Dec 31, 2026), then $349; Wegovy HD 7.2 mg $399	Medication only	Price rises after the intro fills
Foundayo pill (orforglipron), LillyDirect	Starts at $149 for the starting dose, up to $299 at higher doses	Medication only	Some reduced prices run through Dec 31, 2026
Zepbound vial or KwikPen, LillyDirect	$299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) with on-time refills	Medication only	Late refills at higher doses: $499 to $699; a month is 28 days
Compounded semaglutide or tirzepatide, telehealth	Median about $176 all-in (range $79 to $348) across 28 scored programs	Usually membership plus medication	Not FDA-approved; pricing may be flat or rise by dose
Brand with commercial coverage and savings card	As low as $25	Medication	Eligibility rules apply
Medicare GLP-1 Bridge	$50 copay	Medication	For eligible Part D enrollees

Two things jump out. First, the cheapest brand options (the pills at starting doses) now sit right around the typical compounded price. Second, compounded tirzepatide still tends to undercut Zepbound by more than compounded semaglutide undercuts Wegovy, because Zepbound’s self-pay prices start higher.

For deeper price breakdowns by drug, see semaglutide cost without insurance, tirzepatide cost without insurance and medical weight-loss injection costs.

Why the price gap has narrowed

The gap shrank for two reasons, and neither has much to do with compounded prices going up.

The shortages ended. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. That removed the legal basis for pharmacies to make copies at large scale, and many programs changed their products or their claims.

Manufacturers started selling directly to patients. Novo Nordisk’s NovoCare Pharmacy and Eli Lilly’s LillyDirect sell to cash-paying patients without an insurer in the middle, and both priced their newer pills aggressively. The result, according to the price tracker cited above, is that the typical compounded program now costs about the same as a starting-dose brand pill, while the cheapest compounded programs still come in well below the brand floor.

On X, the conversation reflects this split. Some people post that compounded semaglutide has worked for them at under $200 a month. Others share news about quality problems with the ingredients, and many telehealth ads now advertise compounded and FDA-approved options side by side, often with a “compounded, not FDA-approved” line that regulators have pushed for.

Comparing the true cost: four traps to avoid

A price only means something when you compare like with like. These are the most common ways comparisons go wrong.

1. Membership vs medication. Many telehealth programs charge a monthly membership for the clinician and app, and bill medication separately. Manufacturer pharmacies quote a medication price with no membership, but you still need a prescriber, which may cost something. Compare all-in vs all-in.

2. Intro prices. The $199 Wegovy injection price applies to the first two low-dose fills for new patients, then rises to $349. Some compounded programs also run discounted first months. Ask what you will pay in month three and month six.

3. Dose ladders. Brand prices usually climb with dose. Zepbound jumps from $299 at the 2.5 mg starting dose to $449 at 7.5 mg and above. Many compounded programs charge a flat price across doses, which can make them cheaper at higher doses. Compare the price at the dose you are likely to stay on, which only your clinician can estimate.

4. Refill timing and the length of a “month.” LillyDirect counts a Zepbound month as 28 days, and refills later than 45 days at higher doses cost $499 to $699 instead of $449. Over a year, 13 fills of $449 is $5,837, not the $5,388 you would expect from multiplying by 12.

A simple worksheet:

Question	Brand option	Compounded option
Monthly medication price at maintenance dose
Membership or visit fees
Needles, syringes, shipping, labs
Price after intro period
Fills per year (28-day vs 30-day month)
Total for 12 months

What a lower price doesn’t buy: the safety differences

The price difference is only half the comparison. Here is what you give up with a compounded product, based on what FDA and published research report.

No premarket FDA review

FDA states plainly that it does not review compounded drugs for safety, effectiveness or quality before they are sold. Brand-name products went through large clinical trials, and their factories, strength and purity are checked against an approved standard.

Dosing errors from vials

Brand injections come in prefilled pens that deliver a set dose. Many compounded products come in multi-dose vials, so you draw up your own dose with a syringe. FDA has received reports of people taking 5 to 20 times the intended dose, often because instructions used “units” instead of milligrams, or because concentrations differed between pharmacies. Some of those patients needed hospital care for severe vomiting, dehydration, pancreatitis or gallstones. In one example FDA described, a patient prescribed 5 units drew up 50 units instead.

Stanford Medicine clinicians writing in July 2026 noted that poison control centers have seen a more than 15-fold increase since 2019 in calls related to injected weight-loss drugs, many tied to dosing errors that are easier to make with compounded vials.

Quality and purity

Lab studies have found problems in some compounded products:

• A 2026 study in Pharmaceutical Research tested 13 compounded injectable semaglutide products from US sources. Across 8 samples, researchers found 44 impurities, 34 of which were not present in the brand product. One sample contained a component with a mass matching tirzepatide, and another matched insulin glulisine. Under light exposure, strength in two samples dropped to 95% and 86% of the starting level. This study was funded by Novo Nordisk, the maker of Wegovy and Ozempic, and it measured lab quality, not health outcomes in people.
• In October 2026, news reports citing FDA inspection records obtained by Bloomberg described black mold, insect activity and falsified quality records at two Chinese plants that made semaglutide and tirzepatide ingredients for compounded drugs. FDA put both companies on its import alert list.

These findings do not mean every compounded product is contaminated. They mean you cannot tell from the label, and quality can vary from one pharmacy, or one batch, to the next.

Additives and untested forms

FDA is aware of compounders adding vitamin B12, vitamin B6, L-carnitine and NAD to semaglutide, and it says the safety and effectiveness of these combinations have not been established. Stanford’s clinicians also flag sublingual drops and dissolving tablets, which were never studied in clinical trials. Our explainer on compounded GLP-1 oral solutions and drops covers those in detail.

Adverse event reports

As of May 31, 2026, FDA had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. A report does not prove the drug caused the problem, but the numbers are one reason FDA keeps warning patients.

Do compounded GLP-1s work as well?

The honest answer is that nobody knows for sure, because no randomized trial has compared them.

The best available comparison is a retrospective study from a large Australian online weight-loss service, published in Obesities in 2024. Its compounded semaglutide was made under Australian pharmacy board rules and tested monthly by an independent laboratory. Over about four months:

Outcome	Brand semaglutide	Compounded semaglutide
Average weight loss	9.87% (n=1,858)	9.11% (n=923)
Reached 5% weight loss	81.70%	81.15%
Reached 10% weight loss	50.54%	44.64%
Reached 15% weight loss	21.42%	12.78%
Reported any side effect	77.40%	71.61%

The compounded group lost slightly less weight on average, and noticeably fewer people reached 15%. They also reported fewer mild side effects, which could reflect a weaker product or just differences in reporting. Both authors were paid by the company that ran the service, side effects were self-reported, and because compounding varies from pharmacy to pharmacy, one program’s results cannot be applied to compounded semaglutide in general. Australia has since banned compounded copies of GLP-1 drugs, from October 2024.

For context on what the brand drugs did in their main trials, see what is semaglutide and what is tirzepatide.

The legal picture in late 2026

Compounded GLP-1s still exist, but the rules have tightened considerably:

• Shortages are over. Without a shortage, pharmacies generally cannot make what FDA calls “essentially copies” of a commercially available drug.
• Patient-specific compounding remains possible. A state-licensed (503A) pharmacy can compound for an individual patient when a prescriber documents a medical need that an approved drug cannot meet, such as an allergy to an ingredient. Cost alone is not a medical need under the law.
• Large outsourcing facilities face a proposed ban. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk ingredients. Comments closed in July 2026, and as of early November 2026 no final decision had been published.
• Marketing is under scrutiny. On March 3, 2026, FDA announced warning letters to 30 telehealth companies over claims implying their compounded products were the same as FDA-approved drugs, and over branding that obscured who actually made the product.

The practical risk for patients is continuity. A program built on compounded supply may have to change products, prices or stop altogether if rules tighten further, possibly partway through treatment. Stanford’s clinicians advise not stopping a GLP-1 abruptly and asking a clinician how to switch safely, which is a conversation to have with a prescriber rather than something to work out alone.

Who might still pay less with each option

Situation	Often the lower-cost route	What to check
Commercial insurance that covers weight-loss GLP-1s	Brand through insurance, or a savings card (as low as $25)	Prior authorization; see does insurance cover GLP-1s
Medicare Part D, eligible for the GLP-1 Bridge	Brand at a $50 copay	Eligibility rules
No coverage, open to a daily pill	Close call: brand pills start at $149	Price at your maintenance dose
No coverage, wants weekly semaglutide injections	Compounded often cheaper on sticker price	Legal basis, pharmacy licensing, all-in cost
No coverage, wants tirzepatide	Compounded usually cheaper on sticker price	Same as above, plus supply continuity

Whichever way the numbers fall, the medication itself is only part of good care. The decision about which GLP-1, if any, is right for you belongs with a licensed clinician who knows your history; our guide to who should not take GLP-1s explains why.

Questions to ask before choosing

Bring these to any clinic or telehealth program:

1. Is this product FDA-approved, or compounded? If compounded, why is an approved drug not suitable for me?
2. Which pharmacy makes it, and is it state-licensed or an FDA-registered outsourcing facility? Can I see that information before I pay?
3. Is the active ingredient the base form of semaglutide or tirzepatide, or a salt form? Are any other ingredients added?
4. Does it come in a prefilled pen or a vial? If a vial, who will show me how to measure doses, in milligrams, and which syringe should I use?
5. What is the total monthly cost at the dose I’m likely to stay on, including membership, supplies and shipping?
6. What happens to my treatment if your compounded supply stops?

Warning signs include no prescription required, a pharmacy outside the US, prices that seem too good to be true, “research use only” labels, and claims that a compounded product is “the same as” a brand drug. Our list of red flags with online GLP-1 sellers goes further, and how telehealth weight loss works explains what a legitimate program should look like.

The bottom line

Compounded GLP-1s are still cheaper than brand-name ones in many cases, especially at the low end of the market and for tirzepatide. But the typical compounded program now costs about the same as a starting-dose brand pill, and with insurance or Medicare coverage, brand often costs less.

What the price difference does not buy is FDA review, a standard formula, prefilled dosing and a stable legal footing. If cost is what’s steering you toward compounded, first check the manufacturers’ own self-pay prices for the dose you’re likely to need, compare all-in costs, and talk through the options with a licensed clinician. Wegovy and Ozempic are compared in Wegovy vs Ozempic, and the safest GLP-1 for weight loss guide covers how the approved options compare on safety.

Medical disclaimer: This article is for general education and is not medical advice. It does not recommend any specific product, pharmacy, medicine or dose. Prices are self-pay figures published by manufacturers and trackers in fall 2026 and change often, so confirm current pricing before deciding. Talk with a licensed clinician before starting, stopping or switching any medication, and do not stop a medicine prescribed for diabetes without medical guidance.